Correction to: Genet Med advance online publication, 15 March 2018; https://doi.org/10.1038/gim.2018.31

In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng ml−1, α-galactosidase A activity 4.9 nmol h−1 ml−1) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows:

ABSTRACT

Methods:

Page 1, left column line 2; “2,360 patients” was revised to “2,359 patients.”

Page 1, left column lines 2–3; “169 Japanese specialty clinics” was revised to “168 Japanese

specialty clinics.”

Results:

Page 1, right column, line 2; “15 females” was revised to “14 females.”

Page 1, right column, line 4; “8 exhibited” was revised to “7 exhibited.”

MATERIALS AND METHODS

Patient enrollment

Page 2, right column, line 7; “169 clinics” was revised to “168 clinics.”

RESULTS

Study population

Manuscript (All Manuscript Text Pages, including Title Page,

References, and Figure Legends)

Page 3, right column, line 3; “16 patients” was revised to “17 patients.”

Page 3, right column, lines 3–4; “2 patients” was revised to “3 patients.”

Page 3, right column, line 6; “2,360 patients” was revised to “2,359 patients.”

Page 3, right column, line 6; “1,036 females” was revised to “1,035 females.”

Page 3, right column, line 7; “169 clinics” was revised to “168 clinics.”

Plasma lyso-Gb3 levels

Page 4, left column, line 4; “11.5 ng ml−1” was revised to “13.3 ng ml−1.”

Page 4, left column, line 4; “15 females” was revised to “14 females.”

Page 4, left column, line 5; “IQR: 7.8–21.8” was revised to “IQR: 7.9–22.4.”

Plasma α-Gal A activity

Page 4, left column, line 8; “15 females” was revised to “14 females.”

Page 4, left column, line 9; “4.6 nmol h−1 ml−1” was revised to “3.9 nmol h−1 ml−1.”

Page 4, left column, line 9; “IQR: 2.6–6.1” was revised to “IQR: 2.4–6.6.”

Table 1

Table 1 Patients grouped according to the medical specialty of the referring clinic
Full size table

Column Neurology

Females

“(n = 227)” was revised to “(n = 226).”

Clinics (n) “40” was revised to “39.”

Column Total

Females

“(n = 1,036)” was revised to “(n = 1,035).”

Clinics (n) “147” was revised to “146.”

Table 3

Table 3 Frequencies of patients who screened positive for lyso-Gb3 and class 1 GLA mutations, grouped according to the specialty of the referring clinic
Full size table

Column Neurology

Females

Lyso-Gb3-positive patients (%) “2/227 (0.9)” was revised to “1/226 (0.4).”

GLA mutation (%) “1/227 (0.4)” was revised to “1/226 (0.4).”

Column Total

Females

Lyso-Gb3-positive patients (%) “15/1,036 (1.4)” was revised to “14/1,035 (1.4).”

GLA mutation (%) “6/1,036 (0.6)” was revised to “6/1,035 (0.6).”

Figure 1

We revised Figure 1a and b as follows:

Figure 1
figure 1

a Female Positive (n = 15) was replaced with (n = 14), and we deleted the dot plot for one female patient in the positive group (plasma lyso-Gb3 7.6 ng ml−1). Therefore, the median plasma lyso-Gb3 value of Female Positive was changed from “11.5 ng ml−1” to “13.3 ng ml−1.” The position of short horizontal line was also changed. b Female Positive (n = 15) was replaced with (n = 14), and we deleted the dot plot for one female patient in the positive group (plasma α-Gal A activity 4.9 nmol h−1 ml−1). Therefore, the median plasma α-Gal A activity value of Female Positive was changed from “4.6 nmol h−1 ml−1” to “3.9  nmol h−1 ml−1.” The position of the short horizontal line was also changed.

Full size image

SUPPLEMENTARY MATERIAL

Page 6. Supplementary Figure S2. Flowchart of the lyso-Gb3 screening and gene analysis in

female patients.

We revised Supplementary Figure S2 as follows:

The upper square

Female with clinical symptoms suggestive of Fabry disease; “(n = 1036)” was revised

to “(n = 1035).”

Neurology; “(n = 227)” was revised to “(n = 226).”

The second square from the top (left side)

Positive lyso-Gb3 screen; “(n = 15)” was revised to “(n = 14).”

Neurology; “(n = 2)” was revised to “(n = 1).”

The third square from the top (second square from the left)

Normal α-Gal A; “(n = 8)” was revised to “(n = 7).”

Neurology; “(n = 1)” was revised to “(n = 0).”

The fourth square from the top (second square from the left)

“Neurology (n = 1)” was deleted.